文献速递临床试验与 GCP基础与转化研究

原研与他克莫司仿制药在肝、肾移植受者中的生物等效性:随机交叉临床试验

Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
PubMed 文献 · PLoS Med · 2017-11-14

该研究在肾移植(n=35)和肝移植(n=36)受者中开展前瞻性、重复给药、部分盲法、随机、三治疗、六周期交叉生物等效性研究,评估原研他克莫司与两种仿制药(Generic Hi和Generic Lo)的生物等效性。所有产品均符合美国FDA平均生物等效性(ABE)接受标准(90%CI在80.00%-125.00%内),并满足更严格的缩放平均生物等效性(SCABE)标准;欧洲药品管理局(EMA)窄治疗指数药物标准除原研vs Generic Lo的AUC上限略高于111.11%外也均满足。结论支持他克莫司的生物等效性可从健康志愿者转化至肾或肝移植受者,且与原创产品生物等效的仿制药之间也彼此生物等效。

要点

  • 肾移植(n=35)和肝移植(n=36)受者中,原研他克莫司与两种仿制药均符合FDA ABE标准(90%CI 80.00%-125.00%)。
  • 所有产品比较均满足SCABE标准,AUC的90%CI为84.65%-118.13%,Cmax为80.00%-125.00%。
  • EMA窄治疗指数标准除原研vs Generic Lo的AUC上限(肾111.30%、肝112.12%)略高于111.11%外均满足。

核心结论

  • 在肾或肝移植受者中,原研他克莫司与两种仿制药之间以及两种仿制药之间,按现行FDA生物等效性指标均观察到等效。
  • 结果支持窄治疗指数药物他克莫司的生物等效性可从健康志愿者转化至肾或肝移植受者,并提供证据表明与原创产品生物等效的仿制药之间也彼此生物等效。

研究设计与样本

  • 研究于2013年12月至2014年10月在辛辛那提大学开展,为前瞻性、重复给药、部分盲法、随机、三治疗、六周期交叉生物等效性研究。
  • 纳入肾移植受者n=35和肝移植受者n=36。
  • 根据简化新药申请(ANDA)数据(含生产及健康个体药代动力学数据)选择与原创产品差异最大的两种仿制药,命名为Generic Hi和Generic Lo。
  • 研究周期为8周,药代动力学研究评估Generic Hi和Generic Lo与原研他克莫司及彼此间的生物等效性,并评估主要代谢物的生物等效性。

主要发现

  • 所有产品均落在FDA平均生物等效性(ABE)接受标准内,即90%置信区间在80.00%和125.00%置信限内。
  • 所有产品的AUC(范围12.11-15.81)和Cmax(范围17.96-24.72)的个体内变异相似。
  • 计算得出的SCABE 90%置信区间:AUC为84.65%-118.13%,Cmax为80.00%-125.00%。
  • 在肾移植和肝移植受者中,所有产品比较的AUC和Cmax均满足更严格的SCABE接受标准。
  • EMA窄治疗指数药物接受标准亦均满足,唯一例外是原研vs Generic Lo,其90%置信区间上限在肾移植为111.30%、肝移植为112.12%,仅略高于EMA对AUC的接受上限111.11%。

关键数值与推荐

  • FDA ABE接受标准:90%置信区间在80.00%-125.00%内,所有产品均满足。
  • SCABE接受标准:AUC的90%置信区间为84.65%-118.13%,Cmax为80.00%-125.00%,所有产品比较均满足。
  • EMA窄治疗指数药物接受标准:AUC的90%置信区间上限为111.11%;原研vs Generic Lo的AUC上限肾移植为111.30%、肝移植为112.12%,略高于该上限。

临床怎么用

  • 作者结论认为,本研究结果支持他克莫司的生物等效性可从健康志愿者转化至肾或肝移植受者。
  • 作者结论认为,与原创产品生物等效的仿制药之间也彼此生物等效。

局限性

  • 观察在严格控制的条件下进行,不允许不依从或进食对可能的药代动力学差异产生影响。
  • Generic Hi和Lo是根据健康志愿者的生物等效性数据选择的,因为所有产品均无受者的药代动力学数据。
  • 安全性数据应结合参与者数量少和观察期短来解读。
  • 本研究仅使用了1 mg规格的他克莫司。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although the generic drug approval process has a long-term successful track record, concerns remain for approval of narrow therapeutic index generic immunosuppressants, such as tacrolimus, in transplant recipients. Several professional transplant societies and publications have generated skepticism of the generic approval process. Three major areas of concern are that the pharmacokinetic properties of generic products and the innovator (that is, "brand") product in healthy volunteers may not reflect those in transplant recipients, bioequivalence between generic and innovator may not ensure bioequivalence between generics, and high-risk patients may have specific bioequivalence concerns. Such concerns have been fueled by anecdotal observations and retrospective and uncontrolled published studies, while well-designed, controlled prospective studies testing the validity of the regulatory bioequivalence testing approach for narrow therapeutic index immunosuppressants in transplant recipients have been lacking. Thus, the present study prospectively assesses bioequivalence between innovator tacrolimus and 2 generics in individuals with a kidney or liver transplant. METHODS AND FINDINGS: From December 2013 through October 2014, a prospective, replicate dosing, partially blinded, randomized, 3-treatment, 6-period crossover bioequivalence study was conducted at the University of Cincinnati in individuals with a kidney (n = 35) or liver transplant (n = 36). Abbreviated New Drug Applications (ANDA) data that included manufacturing and healthy individual pharmacokinetic data for all generics were evaluated to select the 2 most disparate generics from innovator, and these were named Generic Hi and Generic Lo. During the 8-week study period, pharmacokinetic studies assessed the bioequivalence of Generic Hi and Generic Lo with the Innovator tacrolimus and with each other. Bioequivalence of the major tacrolimus metabolite was also assessed. All products fell within the US Food and Drug Administration (FDA) average bioequivalence (ABE) acceptance criteria of a 90% confidence interval contained within the confidence limits of 80.00% and 125.00%. Within-subject variability was similar for the area under the curve (AUC) (range 12.11-15.81) and the concentration maximum (Cmax) (range 17.96-24.72) for all products. The within-subject variability was utilized to calculate the scaled average bioequivalence (SCABE) 90% confidence interval. The calculated SCABE 90% confidence interval was 84.65%-118.13% and 80.00%-125.00% for AUC and Cmax, respectively. The more stringent SCABE acceptance criteria were met for all product comparisons for AUC and Cmax in both individuals with a kidney transplant and those with a liver transplant. European Medicines Agency (EMA) acceptance criteria for narrow therapeutic index drugs were also met, with the only exception being in the case of Brand versus Generic Lo, in which the upper limits of the 90% confidence intervals were 111.30% (kidney) and 112.12% (liver). These were only slightly above the upper EMA acceptance criteria limit for an AUC of 111.11%. SCABE criteria were also met for the major tacrolimus metabolite 13-O-desmethyl tacrolimus for AUC, but it failed the EMA criterion. No acute rejections, no differences in renal function in all individuals, and no differences in liver function were observed in individuals with a liver transplant using the Tukey honest significant difference (HSD) test for multiple comparisons. Fifty-two percent and 65% of all individuals with a kidney or liver transplant, respectively, reported an adverse event. The Exact McNemar test for paired categorical data with adjustments for multiple comparisons was used to compare adverse event rates among the products. No statistically significant differences among any pairs of products were found for any adverse event code or for adverse events overall. Limitations of this study include that the observations were made under strictly controlled conditions that did not allow for the impact of nonadherence or feeding on the possible pharmacokinetic differences. Generic Hi and Lo were selected based upon bioequivalence data in healthy volunteers because no pharmacokinetic data in recipients were available for all products. The safety data should be interpreted in light of the small number of participants and the short observation periods. Lastly, only the 1 mg tacrolimus strength was utilized in this study. CONCLUSIONS: Using an innovative, controlled bioequivalence study design, we observed equivalence between tacrolimus innovator and 2 generic products as well as between 2 generic products in individuals after kidney or liver transplantation following current FDA bioequivalence metrics. These results support the position that bioequivalence for the narrow therapeutic index drug tacrolimus translates from healthy volunteers to individuals receiving a kidney or liver transplant and provides evidence that generic products that are bioequivalent with the innovator product are also bioequivalent to each other. TRIAL REGISTRATION: ClinicalTrials.gov NCT01889758.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Alloway RR, Vinks AA, Fukuda T, et al. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial. PLoS Med. 2017. PMID: 29135993. doi:10.1371/journal.pmed.1002428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。